Checkpoint Therapeutics Inc (CKPT)
2.22
+0.04
(+1.83%)
USD |
NASDAQ |
Oct 04, 16:00
2.225
0.00 (0.00%)
After-Hours: 20:00
Checkpoint Therapeutics SG&A Expense (Annual): 8.685M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.685M |
| December 31, 2022 | 8.70M |
| December 31, 2021 | 8.538M |
| December 31, 2020 | 7.918M |
| December 31, 2019 | 7.233M |
| Date | Value |
|---|---|
| December 31, 2018 | 6.592M |
| December 31, 2017 | 5.419M |
| December 31, 2016 | 4.467M |
| December 31, 2015 | 2.488M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.233M
Minimum
2019
8.70M
Maximum
2022
8.215M
Average
8.538M
Median
2021
SG&A Expense (Annual) Benchmarks
| Fortress Biotech Inc | 94.12M |
| Avenue Therapeutics Inc | 4.179M |
| Journey Medical Corp | 43.91M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 12.27M |